Markets:

Overview

News

Currencies

International

Treasuries

Royal Bank of Canada (TSX:RY)

205.46 -0.39 (-0.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Royal Bank of Canada

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

28 29 Next >

Navigating Discover's Merger With Capital One: Analyst Highlights Opportunities And Challenges Ahead ↗

February 22, 2024

RBC Capital Markets downgrades Discover Financial to Sector Perform with increased price target of $140. Merger with Capital One expected to be accretive and generate $2.7B in synergies. Analyst sees...

Via Benzinga

Here's How Much You Would Have Made Owning RBC Bearings Stock In The Last 15 Years ↗

February 21, 2024

Via Benzinga

This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space ↗

February 16, 2024

Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset...

Via Benzinga

RBC Capital Maintains Sector Perform Rating for NMI Holdings: Here's What You Need To Know ↗

February 15, 2024

Via Benzinga

RBC Illuminates Solar Sector, Launches Coverage For 4 Solar Equipment Leaders ↗

February 14, 2024

RBC Capital Markets highlighted favorable public policy and declining costs within the solar industry and initiated coverage on several solar equipment suppliers, including First Solar, Enphase Energy,...

Via Benzinga

Topics Supply Chain

Preview: RBC Bearings's Earnings ↗

February 07, 2024

Via Benzinga

The Weird And Depressing Debate Over AS/AD ↗

January 23, 2024

I didn’t know that hardcore RBC types had a view on this question, but today I’m more interested in Tyler’s comment on aggregate demand.

Via Talk Markets

RBC Capital Maintains Outperform Rating for Datadog: Here's What You Need To Know ↗

February 14, 2024

Via Benzinga

Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month ↗

February 09, 2024

"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins...

Via Benzinga

RBC Capital's Rating Upgrade Propels IGM Biosciences Into Immunology Limelight ↗

February 09, 2024

IGM Biosciences' strategic shift to immunology with promising bispecific drug, imvotamab. RBC Capital upgraded stock to Outperform, anticipating $21 price target. Data expected in 2H 2024 validates its...

Via Benzinga

RBC Capital Maintains Sector Perform Rating for Thomson Reuters: Here's What You Need To Know ↗

February 09, 2024

Via Benzinga

RBC Capital Maintains Outperform Rating for Ensign Group: Here's What You Need To Know ↗

February 06, 2024

Via Benzinga

Uber, Lyft Can Hitch A Ride Higher If Q4 Earnings Beat Wall Street Estimates ↗

February 05, 2024

Uber reports on Wednesday, while Lyft Q4s are on Feb. 13. RBC has a sector perform rating on Lyft and an outperform rating on Uber.

Via Benzinga

Topics Earnings

Capstone Copper Announces Multimillion-Dollar Financing To Support Its Chilean Expansion ↗

February 05, 2024

Capstone Copper Corp. and Orion Mine Finance arranged a CA$375 million bought deal with RBC Capital Markets, expected to close on Feb. 8, 2024.

Via Benzinga

RBC Capital Maintains Outperform Rating for Reinsurance Gr: Here's What You Need To Know ↗

February 05, 2024

Via Benzinga

RBC Capital Maintains Sector Perform Rating for Bio-Techne: Here's What You Need To Know ↗

February 02, 2024

Via Benzinga

RBC Capital Maintains Outperform Rating for Thermo Fisher Scientific: Here's What You Need To Know ↗

February 01, 2024

Via Benzinga

What's In Store For Clorox This Earnings Season? Analyst Sees Issues With Trash Bags, Cat Litter & More ↗

January 30, 2024

Clorox faces challenges in key product categories like trash bags and cat litter, hindering recovery from the 2023 cyber-attack, according to RBC analyst Nik Modi.

Via Benzinga

'We Stay The Course On Meta And Amazon': Analysts Preview Tech Earnings ↗

January 29, 2024

RBC is looking for acceleration in Amazon's AWS cloud offering and expects increasing adoption of Advantage+ to be a key driver of Meta.

Via Benzinga

Foresight to Participate in A.G.P’s Virtual Technology Conference

January 29, 2024

--News Direct--

Via News Direct

Topics Regulatory Compliance

Foresight to Participate in A.G.P’s Virtual Technology Conference

January 29, 2024

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“FRSX” or the “Company”), an innovator in automotive vision systems, today announced that management will participate in the Alliance Global...

Via TheNewswire.com

Topics Regulatory Compliance

RBC Capital Maintains Outperform Rating for Popular: Here's What You Need To Know ↗

January 26, 2024

Via Benzinga

Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says ↗

January 25, 2024

Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates.

Via Benzinga

RBC Capital Maintains Outperform Rating for ServiceNow: Here's What You Need To Know ↗

January 25, 2024

Via Benzinga

Post Event Report - The Future of Insurance Canada 2023

January 25, 2024

London, United Kingdom--(Newsfile Corp. - January 25, 2024) - In 2023 business was anything but as usual. Spiraling costs, accelerated...

Via Newsfile

RBC Capital Maintains Sector Perform Rating for Procter & Gamble: Here's What You Need To Know ↗

January 24, 2024

Via Benzinga

Rio Tinto and BHP stock: Can mining giants unearth profit growth?

January 18, 2024

Analysts and mining company CEOs are upbeat about the global market for copper, iron ore and other metals, despite mining stocks' recent price declines.

Via MarketBeat

Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development ↗

January 12, 2024

89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties.

Via Benzinga

RBC Capital Upgrades Taylor Morrison Home: Here's What You Need To Know ↗

January 12, 2024

Via Benzinga

RBC Capital Maintains Outperform Rating for Realty Income: Here's What You Need To Know ↗

January 11, 2024

Via Benzinga

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.